Table 2.
Association of STC1 and STC2 expression with breast cancer recurrence.
| Expression of STC1 or STC2a | ER+/TAM+
|
ER−/TAM−
|
||||
|---|---|---|---|---|---|---|
| Recurrent cases/ controls | OR (95% CI)b | Adjusted OR (95% CI)c | Recurrent cases/ controls | OR (95% CI)b | Adjusted OR (95% CI)c,d | |
|
|
|
|||||
| STC1 | 440/444 | 1.05 (0.80, 1.38) | 1.04 (0.79, 1.38) | 252/253 | 1.08 (0.72, 1.60) | 0.99 (0.65, 1.51) |
| STC2 | 415/423 | 0.72 (0.54, 0.96) | 0.73 (0.54, 0.98) | 245/237 | 0.92 (0.63, 1.34) | 0.90 (0.60, 1.36) |
| STC1e | 409/415 | 1.11 (0.84, 1.48) | 1.11 (0.83, 1.48) | 244/234 | 1.11 (0.74, 1.68) | 1.05 (0.67, 1.62) |
| STC2e | 409/415 | 0.71 (0.53, 0.96) | 0.72 (0.53, 0.98) | 244/234 | 0.89 (0.61, 1.30) | 0.89 (0.58, 1.34) |
a
Expression of STC1 and STC2 dichotomized as positive (>0%) or negative (0%).
b
OR from unconditional logistic regression, controlling for matched factors: age group, year group of diagnosis, menopausal status, Stage (I–III), and county of treatment.
c
Adjusted OR includes adjustment for all matched factors and chemotherapy, radiation, CCI group, and tamoxifen duration (ER+).
d
Adjusted ORs resulted in a different number of cases/controls than matched ORs for ER−/TAM− group. For STC1=248/219, STC2=236/199, in combination=240/203.
e
STC1 and STC2 expression tested within same logistic model.